KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Common Equity (2016 - 2026)

TherapeuticsMD filings provide 17 years of Common Equity readings, the most recent being $27.0 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 0.87% to $27.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $27.0 million, a 0.87% increase, with the full-year FY2025 number at $26.9 million, down 1.8% from a year prior.
  • Common Equity hit $27.0 million in Q1 2026 for TherapeuticsMD, roughly flat from $26.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $35.1 million in Q4 2022 to a low of -$140.6 million in Q1 2022.
  • Median Common Equity over the past 5 years was $27.4 million (2024), compared with a mean of $11.0 million.
  • Biggest five-year swings in Common Equity: crashed 1383.22% in 2022 and later surged 219.68% in 2023.
  • TherapeuticsMD's Common Equity stood at $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then fell by 6.55% to $27.4 million in 2024, then dropped by 1.8% to $26.9 million in 2025, then rose by 0.36% to $27.0 million in 2026.
  • The last three reported values for Common Equity were $27.0 million (Q1 2026), $26.9 million (Q4 2025), and $27.4 million (Q3 2025) per Business Quant data.